Chi Young Ok, M.D.

Peer-Reviewed Articles

1. Weinberg OK, Chisholm KM, Ok CY, Fedoriw Y, Grzywacz B, Kurzer JH, Mason EF, Moser KA, Bhattacharya S, Xu M, Babu D, Foucar K, Tam W, Bagg A, Orazi A, George TI, Wang W, Wang SA, Arber DA, Hasserjian RP. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Mod Pathol 34(7):1358-1366, 2021. e-Pub 2021. PMID: 33526873.
2. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1-12, 2021. e-Pub 2021. PMID: 33480830.
3. Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML.. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. American Journal of Hematology 96(5):E137-E140, 2021. e-Pub 2021. PMID: 33491779.
4. Fang H, Medeiros LJ, Tang Z, Wang W, Ok CY, Patel KP, Khoury JD, Thakral B. From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later. Annals of Diagnostic Pathology 50:151649, 2021. e-Pub 2020. PMID: 33189964.
5. Ok CY, Trowell KT, Parker KG, Moser K, Weinberg OK, Rogers HJ, Reichard KK, George TI, Hsi ED, Bueso-Ramos CE, Tam W, Orazi A, Bagg A, Arber DA, Hasserjian RP, Wang SA.. Pathologic Spectrum of Chronic Myeloid Neoplasms Harboring Concomitant Mutations in Myeloproliferative Neoplasm Driver Genes (JAK2/MPL/CALR) and SF3B1. Modern Pathology 34(1):20-31, 2021. e-Pub 2020. PMID: 32694616.
6. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P.. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
7. Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Sasaki K, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R.. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo Acute Myeloid Leukemia with mutated RUNX1. Modern Pathology 33(9):1678-1689, 2020. PMID: 32238878.
8. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML.. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances 4(6):1038-1050, 2020. PMID: 32191807.
9. Sakhdari A, Loghavi S, Thakral B, Kanagal-Shamanna R, Yin CC, Zhuang Z, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Ok CY.. RAS and TP53, not NOTCH1, Can Predict Survival in Adults with T-Cell Lymphoblastic Leukemia Treated with Hyper-CVAD. Cancer Med 9(3):849-858, 2020. e-Pub 2019. PMID: 31804006.
10. Chen Z, Ok CY, Wang W, Goswami M, Tang G, Routbort M, Jorgensen JL, Medeiros LJ, Wang SA. Low-Grade Myelodysplastic Syndromes With Preserved CD34+ B-Cell Precursors (CD34+ Hematogones). Cytometry B Clin Cytom 98(1):36-42, 2020. e-Pub 2019. PMID: 31211490.
11. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
12. Chen Z, Wang SA, Goswami M, Tang G, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Ok CY.. Comparison of Therapy-Related Myelodysplastic Syndrome With Ring Sideroblasts and De Novo Myelodysplastic Syndrome With Ring Sideroblasts. Leuk Res 86:106227, 2019. PMID: 31557598.
13. Kim DH, Medeiros LJ, Aung PP, Young KH, Miranda RN, Ok CY. Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases. Am J Surg Pathol 43(10):1421-1428, 2019. e-Pub 2019. PMID: 31219818.
14. Sakhdari A, Tang Z, Ok CY, Bueso-Ramos CE, Medeiros LJ, Huh YO. Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Cancer Genet 238:18-22, 2019. e-Pub 2019. PMID: 31425921.
15. Weinberg OK, Hasserjian RP, Baraban E, Ok CY, Geyer JT, Philip JKSS, Kurzer JH, Rogers HJ, Nardi V, Stone RM, Garcia JS, Hsi ED, Bagg A, Wang SA, Orazi A, Arber DA. Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol 32(9):1373-1385, 2019. e-Pub 2019. PMID: 31000771.
16. Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JD. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol 186(4):538-548, 2019. e-Pub 2019. PMID: 31115909.
17. Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol 94(7):757-766, 2019. e-Pub 2019. PMID: 30963592.
18. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
19. Sakhdari A, Moghaddam PA, Ok CY, Walter O, Tomaszewicz K, Caporelli ML, Meng X, LaFemina J, Whalen G, Belkin E, Zivny J, Wassef W, Woda BA, Hutchinson LM, Cosar EF. Somatic molecular analysis augments cytologic evaluation of pancreatic cyst fluids as a diagnostic tool. Oncotarget 10(40):4026-4037, 2019. e-Pub 2019. PMID: 31258847.
20. Tang Z, Tang G, Hu S, Patel KP, Cameron Yin C, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Jeffrey Medeiros L. Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies. Data Brief 24:104025, 2019. e-Pub 2019. PMID: 31193989.
21. Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu S, Routbort MJ, Luthra R, Medeiros LJ, Khoury JD, Loghavi S. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol 41:38-42. e-Pub 2019. PMID: 31132650.
22. O'Malley DP, Dogan A, Fedoriw Y, Medeiros LJ, Ok CY, Salama ME. American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma. Ann Diagn Pathol 39:105-110, 2019. e-Pub 2019. PMID: 30802809.
23. Tang Z, Tang G, Hu S, Patel KP, Yin CC, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Medeiros LJ. Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. Cancer Genet 233-234:21-31, 2019. e-Pub 2019. PMID: 31109591.
24. Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Tang G, Tang Z, Jorgensen JL, Luthra R, Ravandi F, Kantarjian HM, DiNardo CD, Medeiros LJ, Wang SA, Patel KP. Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica 104(2):305-311, 2019. e-Pub 2018. PMID: 30171025.
25. Ok CY, Medeiros LJ, Thakral B, Tang G, Jain N, Jabbour E, Pierce SA, Konoplev S. High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma. Mod Pathol 32(1):48-58, 2019. e-Pub 2018. PMID: 30181564.
26. Patel KP, Ruiz-Cordero R, Chen W, Routbort MJ, Floyd K, Rodriguez S, Galbincea J, Barkoh BA, Hatfield D, Khogeer H, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, DiNardo CD, Luthra R, Medeiros LJ. Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection. J Mol Diagn 21(1):89-98, 2019. PMID: 30577887.
27. Garces S, Khoury JD, Kanagal-Shamanna R, Salem A, Wang SA, Ok CY, Hu S, Patel KP, Routbort MJ, Luthra R, Tang G, Schlette EJ, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Hum Pathol 82:215-231, 2018. e-Pub 2018. PMID: 30086334.
28. Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578-587, 2018. e-Pub 2018. PMID: 30175400.
29. Mi X, Griffin G, Lee W, Patel S, Ohgami R, Ok CY, Wang S, Geyer JT, Xiao W, Roshal M, Garcia JS, Silverman LB, Sallan SE, Aster JC, Harris MH, Weinberg OK. Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. Am J Hematol 93(11):1358-1367, 2018. e-Pub 2018. PMID: 30117174.
30. Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin CC, Kanagal-Shamanna R, Wang SA, Jorgensen JL, Medeiros LJ, Ok CY. Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget 9(9):8441-8449, 2018. e-Pub 2018. PMID: 29492206.
31. Wang W, Routbort MJ, Tang Z, Ok CY, Patel KP, Daver N, Garcia-Manero G, Medeiros LJ, Wang SA. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. Eur J Haematol 99(6):536-543, 2017. e-Pub 2017. PMID: 28926144.
32. Wang W, Routbort MJ, Ok CY, Patel KP, Sun Y, Kanagal-Shamanna R, Medeiros LJ, Wang SA. Characterization of TP53 mutations in clonal cytopenia of undetermined significance. Am J Hematol 92(8):E175-E177, 2017. e-Pub 2017. PMID: 28494520.
33. Margolskee E, Hasserjian RP, Hassane D, Tam W, Mathew S, Ok CY, Wang SA, Oak J, Arber DA, Orazi A. Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. Am J Clin Pathol 148(1):49-57, 2017. PMID: 28927162.
34. Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam GC, Xu X, Tzankov A, Hsi ED, Møller MB, Medeiros LJ, Ok CY, Young KH. NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol 30(6):854-876, 2017. e-Pub 2017. PMID: 28281555.
35. Joo JW, Konoplev S, McDonnell TJ, Ok CY.. B-acute lymphoblastic leukemia/lymphoma (B-ALL) with precedent or concurrent myelodysplastic syndrome (MDS) with deletion 5q. J of Hematopathology 10(2):75-80, 2017.
36. Ok CY, Young KH. Checkpoint inhibitors in hematological malignancies. J Hematol Oncol 10(1):103, 2017. e-Pub 2017. PMID: 28482851.
37. Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Zhang L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Westin J, Fowler N, Miranda RN, Ok CY, Li J, Medeiros LJ, Young KH. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis for activated B-cell-like diffuse large B-cell lymphoma. Leukemia 31(3):625-636, 2017. e-Pub 2016. PMID: 27568520.
38. Ok CY, Young KH. Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev 54:99-109, 2017. e-Pub 2017. PMID: 28242522.
39. Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Young Ok C, Salim AA, Routbort MJ, Mehrotra M, Verstovsek S, Medeiros LJ, Luthra R, Patel KP. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. Am J Clin Pathol 145(3):418-27, 2016. PMID: 27124925.
40. Jain P, Ok CY, Konoplev S, Patel KP, Jorgensen J, Estrov Z, Luthra R, Kantarjian H, Ravandi F. Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?. J Clin Oncol 34(7), 2016. e-Pub 2014. PMID: 24982452.
41. Ok CY, Leventaki V, Wang SA, Dinardo C, Medeiros LJ, Konoplev S. Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy. Am J Clin Pathol 145(2):271-6, 2016. e-Pub 2016. PMID: 26800764.
42. Ohanian M, Bueso-Ramos C, Ok CY, Lin P, Patel K, Alattar ML, Khoury JD, Rozovski U, Estrov Z, Huh YO, Cortes J, Abruzzo LV. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet 208(11):571-4, 2015. e-Pub 2015. PMID: 26382622.
43. Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, McDonnell TJ, Ok CY, Kantarjian HM, Medeiros LJ, Hu S. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood 126(14):1699-706, 2015. e-Pub 2015. PMID: 26243778.
44. Yabe M, Medeiros LJ, Wang SA, Konoplev S, Ok CY, Loghavi S, Lu G, Flores L, Khoury JD, Cason RC, Young KH, Miranda RN. Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of γδ T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With γδ T-Cell Large Granular Lymphocytic Leukemia. Am J Clin Pathol 144(4):607-19, 2015. PMID: 26386082.
45. Li L, Xu-Monette ZY, Ok CY, Tzankov A, Manyam GC, Sun R, Visco C, Zhang M, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Wang J, Parsons BM, Winter JN, Piris MA, Pham LV, Medeiros LJ, Young KH. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget 6(27):23157-80, 2015. PMID: 26324762.
46. Ok CY, Xu-Monette ZY, Li L, Manyam GC, Montes-Moreno S, Tzankov A, Visco C, Dybkær K, Routbort MJ, Zhang L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Rao H, Møller MB, Winter JN, Piris MA, Wang SA, Medeiros LJ, Young KH. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol 28(9):1202-13, 2015. e-Pub 2015. PMID: 26111978.
47. Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?. Oncotarget 6(16):13933-45, 2015. PMID: 26101854.
48. Cleven AH, Nardi V, Ok CY, Goswami M, Dal Cin P, Zheng Z, Iafrate AJ, Abdul Hamid MA, Wang SA, Hasserjian RP. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol 28(4):552-63, 2015. e-Pub 2014. PMID: 25412846.
49. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, Goswami M, Singh R, Kanagal-Shamanna R, Pierce SA, Young KH, Kantarjian HM, Medeiros LJ, Luthra R, Wang SA. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res 39(3):348-54, 2015. e-Pub 2014. PMID: 25573287.
50. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SA. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol 8:45, 2015. e-Pub 2015. PMID: 25952993.
51. Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, Visco C, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Zhao X, Ponzoni M, Ferreri AJ, Bertoni F, Farnen JP, Møller MB, Piris MA, Winter JN, Medeiros LJ, Young KH. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res 20(19):5113-23, 2014. e-Pub 2014. PMID: 25124685.
52. Ok CY, Wang SA, Amin HM. Leukemic phase of ALK(+) anaplastic large-cell lymphoma, small-cell variant: clinicopathologic pitfalls of a rare entity. Clin Lymphoma Myeloma Leuk 14(4):e123-6, 2014. e-Pub 2014. PMID: 24685107.
53. Ok CY, Yin CC, Yabe M, Bueso-Ramos CE, Miranda RN, Medeiros LJ, Konoplev SN. Lymphoma with features intermediate between aggressive T-large granular lymphocytic leukemia and hepatosplenic T-cell lymphoma: a diagnostic dilemma?. Clin Lymphoma Myeloma Leuk 14(3):e95-e100, 2014. e-Pub 2014. PMID: 24524924.
54. Strati P, Manning JT, Ok CY, Garcia-Manero G, Estrov Z. Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia. Leuk Lymphoma 55(6):1425-7, 2014. e-Pub 2014. PMID: 23987820.
55. Ok CY, Xu-Monette ZY, Tzankov A, O'Malley DP, Montes-Moreno S, Visco C, Møller MB, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Han van Krieken J, Ponzoni M, Farnen JP, Piris MA, Winter JN, Medeiros LJ, Young KH. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer 120(12):1818-1829, 2014. e-Pub 2014. PMID: 24648050.
56. Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC, Montes-Moreno S, Dybkaer K, Dybaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Chen J, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ai W, Ponzoni M, Ferreri AJ, Farnen JP, Møller MB, Bueso-Ramos CE, Miranda RN, Winter JN, Piris MA, Medeiros LJ, Young KH. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res 20(9):2338-2349, 2014. e-Pub 2014. PMID: 24583797.
57. Ok CY, Hasserjian RP, Foz PS, Stinhgo F, Zuo Z, Young KH, Patel IK, Medeiros LJ, Garcia-Manero G, Wang SA. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 28(1):185-189, 2014. e-Pub 2013. PMID: 23787392.
58. Fu B, Ok CY, Goswami M, Xei W, Jaso JM, Muzzafar T, Bueso-Ramos C, Verstovsek S, Garcia-Manero G, Medeiros LJ, Wang SA. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Ann Hematol 92(10):1335-43, 2013. e-Pub 2013. PMID: 23660629.
59. Ok CY, Papathomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood 122(3):328-40, 2013. e-Pub 2013. PMID: 23649469.
60. Yu H, Ok CY, Hesse A, Nordell P, Connor D, Sjostedt E, Pechet L, Snyder LM. Evaluation of an automated digital imaging system, Nextslide Digital Review Network, for examination of peripheral blood smears. Arch Pathol Lab Med 136(6):660-7, 2012. PMID: 22646275.
61. Ok CY, Akalin A. Gastric heterotopia in the rectum. Journal of Medical Cases 3(2):113-115, 2012.
62. Ok CY, Singh RR, Vega F. Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am J Pathol 180(1):2-11, 2012. e-Pub 2011. PMID: 22056910.
63. Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC, Garcia-Manero G, Wang SA, Hasserjian RP. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 30(19):2340-7, 2012. PMID: 22585703.
64. Ok CY, Medeiros LJ, Hu Y, Bueso-Ramos CE, Wang SA. Transient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignancies. Leuk Res 35(12):1605-10, 2011. e-Pub 2011. PMID: 21596435.
65. Hao S, Smith TW, Chu PG, Liu Q, Ok CY, Woda BA, Lu D, Lin P, Wang SA, Dresser K, Rock KL, Jiang Z. The oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma. Arch Pathol Lab Med 135(8):1032-6, 2011. PMID: 21809995.

Invited Articles

1. Ok CY and Medeiros LJ. High-Grade B-cell Lymphoma: A Term Re-purposed in the Revised WHO Classification. Pathology 52(1):68-77, 2020. PMID: 31735344.
2. Ok CY, Li L, Young KH. EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med 47(1):e132, 2015. e-Pub 2015. PMID: 25613729.

Manuals, Teaching Aids, Other Teaching Publications

1. Khanlari M, Ok CY.. Mantle cell lymphoma-Aggressive variants. PathologyOutlines.com, 2020.
2. Khanlari M, Ok CY.. Mantle cell lymphoma-Classic. PathologyOutlines.com, 2020.

Editorials

1. Ok CY, Young KH. Age cutoff in lymphoma diagnosis. Aging (Albany NY) 7(7):451-2, 2015. PMID: 26187891.

Abstracts

1. OK CY, Trowell KT, Parker KG, Moser K, Weinberg OK, Rogers HJ, Reichard KK, George TI, Hsi ED, Bueso-Ramos CE, Tam W, Orazi A, Bagg A, Arber DA, Hasserjian RP, Wang SA.. Pathologic Spectrum of Chronic Myeloid Neoplasms Harboring Concomitant Mutations in Myeloproliferative Neoplasm Driver Genes (JAK2/MPL/CALR) and SF3B1. The United States and Canadian Academy of Pathology Annual Meeting, 2020.
2. Xie W, Sakhdari A, Loghavi S, Kanagal-Shamanna R, Zuo Z, Yin CC, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Ok CY.. The Result of 122 Consecutive NGS-based Analysis of T-Lymphoblastic Leukemia/Lymphoma and Early T-cell Precursor Leukemia. The Association of Molecular Pathology Annual Meeting, 2019.
3. Sakhdari A, Young KH, Miranda RN, Medeiros LJ, Ok CY.. Enhancer of Zeste Homolog 2 (EZH2) Expression in Mantle Cell Lymphoma Correlates with Ki-67 Proliferation Rate, but Does Not Correlate with Trimethylation of Histone H3 at Lysine 27. The United States and Canadian Academy of Pathology Annual Meeting, 2019.
4. OK CY, Chen Z, Loghavi S, Kanagal-Shamanna R, Zhuang Z, Yin CC, Routbort M, Patel KP, Luthra R. Medeiros LJ, Wang SA.. Prevalence and Clinical Implications of Splicing Factor Gene Mutation in Patients with Primary Myelofibrosis. The United States and Canadian Academy of Pathology Annual Meeting, 2019.
5. Jain P, Kanagal-Shamanna R, Zhang SJ, Ok CY, Gonzalez GMN, Ahmed M, Omarya GP, Ghorab A, Boddu PC, Chen W, Lee HJ, Badillo M, Nomie K, Fayad L, Nastoupil LJ, Champlin RE, Neelapu SS, Patel K, Medeiros LJ, Romaguera JE, Fowler NH, Wang LH, Wang M. Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. BLOOD-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018.
6. Weinberg OK, Hasserjian RP, Baraban, E (Baraban, Ezra); Ok, CY (Ok, Chi Young); Geyer, JT (Geyer, Julia T.); Philip, JKSS (Philip, John K. S. S.); Kurzer, JH (Kurzer, Jason H.); Rogers, HJ (Rogers, Heesun J.); Nardi, V (Nardi, Valentina); Stone, RM (Stone, Richard M.); Garcia, JS (Garcia, Jacqueline S.); Hsi, ED (Hsi, Eric D.); Bagg, A (Bagg, Adam); Wang, SA (Wang, Sa A.); Orazi, A (Orazi, Attilio); Arber, DA (Arber, Daniel A.). Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. BLOOD-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018.
7. Makhdum Ahmed, Hui Guo, Shaojun Zhang, Lalit Sehgal, Preetesh Jain, Rashmi Kanagal-Shamanna, Chi Young Ok, Angela Leeming, Yixin Yao, Liang Zhang, Krystle Nomie, Linghua Wang, Michael Wang. Unravelling the Heterogeneity of Mantle Cell Lymphoma Ecosystem By Single Cell RNA Sequencing. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018.
8. Jain P, Kanagal-Shamanna R, Zhang SJ, Ok CY, Ahmed M, Nava D, Badillo M, Nomie K, Patel K, Lee HJ, Hagemeister FB, Fayad L, Nastoupil LJ, Medeiros LJ, Neelapu SS, Romaguera JE, Fowler NH, Wang LH, Wang M. Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018.
9. Ruiz-Cordero R, Floyd K, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Luthra R, Kantarjian HM, Medeiros LJ, Patel KP, Ok CY. PTPN11 Mutation is Uncommon in Acute Myeloid Leukemia, but Associated with a Complex Karyotype, Co-mutations in KRAS or NRAS and Poor Prognosis. Journal of Molecular Diagnostics 20(6):930-931, 2018.
10. Sakhdari A, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort M, Patel KP, Luthra R, Medeiros LJ, Ok CY. RAS and TP53, Not NOTCH1, Can Predict Survival in Adults with Acute T-Cell Lymphoblastic Leukemia Treated with Hypercvad. BLOOD-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018.
11. Thakral B, Muzzafar T, Badar I, Wang S, Miranda R, Lin P, Khoury J, Routbort M, Kanagal-Shamanna R, Loghavi S, Ok CY, Yin CC, Zuo Z, Verstovsek S, Benton C, Luthra R, Bueso-Ramos C, Medeiros LJ, Patel K. Clinicopathologic and Molecular Characteristics of Myeloid Neoplasms with Non-Canonical MPL Mutations. Laboratory Investigation-106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 98(Supplement 1):559-560, 2018.
12. Sakhdari A, Routbort M, Bueso-Ramos C, Patel K, Luthra R, Ok CY, Loghavi S, Zuo Z, Yin CC, Khoury J, Medeiros LJ, Kanagal-Shamanna R. Myelodysplastic Syndromes with EZH2 Mutations Frequently Show Multilineage Dysplasia, Chromosome 7 Alterations and Concomitant Mutations in ASXL1, RUNX1 and TET2. Modern Pathology-107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 31(Supplement 2):549-550, 2018.
13. Sakhdari A, Patel K, Ok CY, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu SM, Routbort M, Luthra R, Medeiros LJ, Khoury J, Loghavi S. TP53 Mutations are Common in Mantle Cell Lymphoma, Including the Indolent Leukemic Non-Nodal Variant. Modern Pathology-107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 31(Supplement 2):549-549, 2018.
14. Ruiz-Cordero R, Hidalgo-Lopez JE, Bueso-Ramos C, Routbort M, Kanagal-Shamanna R, Zuo Z, Yin CC, Loghavi S, Ok CY, Jorgensen J, Wang S, Tang GL, Luthra R, Medeiros LJ, Patel K. Distinct Genetic Features of Myelodysplastic Syndromes as Defined in the Revised 2016 World Health Organization Classification. Modern Pathology-107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 31(Supplement 2):549-549, 2018.
15. Quesada AE, DiNardo C, Routbort M, Bueso-Ramos C, Kanagal-Shamanna R, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang S, Benton C, Kantarjian HM, Luthra R, Medeiros LJ, Patel K. DDX41 Mutations in Myeloid Neoplasms Are Associated with Male Predominance, TP53 mutation and a High Risk of Progression to AML. Modern Pathology 31(Supplement 2):545-545, 2018.
16. Hu BY, Patel K, Wang XM, Chen HC, Thompson PA, Keating MJ, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Luthra R, Routbort M, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Wierda WG. Standardized Targeted Sequencing of 29 Genes with Recurrent Mutations in Chronic Lymphocytic Leukemia (CLL) Helps to Better Define Clinical Correlates and Genomic Hotspots. Blood-59th Annual Meeting of the American Society of Hematology (ASH) 130(Supplement 1), 2017.
17. Romaguera JE, Lee HJ, Tarapore R, Prabhu VV, Allen JE, Schalop L, Zloza A, Ok CY, Badillo M, Wang M. Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment. Blood-59th Annual Meeting of the American-Society-of-Hematology (ASH) 130(Supplement 1), 2017.
18. Ok CY, Singh R, Luthra R, Hatfield D, Floyd K, Loghavi S, Kanagal-Shamanna R, Zuo Z, Yin CC, Routbort M, Kantarjian HM, Medeiros LJ, Patel KP. Endleukemia Assay v1: Enabling NGS-Based Comprehensive Routine Molecular Profiling of Leukemias in Routine Clinical Care. Blood-59th Annual Meeting of the American Society of Hematology (ASH) 130(Supplement 1), 2017.
19. Ruiz-Cordero R, Chen W, Floyd KC, Rodriguez S, Galbincea J, Barkoh B, Routbort M, Luthra R, Singh R, Hatfield D, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, Medeiros J, Patel KP. Breaking the Turnaround Time Barrier in Next Generation Sequencing Based Clinical Mutation Profiling Using an Integrated Workflow and Informatics Approach. Journal of Molecular Diagnostics-Annual Meeting of the Association for Molecular Pathology (AMP) 19(6):997-998, 2017.
20. Kanagal-Shamanna R, Luthra R, Routbort MJ, Singh R, Floyd K, Abraham R, Hai S, Yin C, Zuo Z, Ok CY, Loghavi S, Medeiros L, Patel KP. Multi-Platform-Based Comprehensive Molecular Analysis of Hematological Malignancies for Somatic Mutations, Copy Number Changes and Translocations for Routine Clinical Testing. Journal of Molecular Diagnostics-Annual Meeting of the Association for Molecular Pathology (AMP) 19(6):964-964, 2017.
21. Wang W, Routbort MJ, Ok CY, Patel KP, Luthra R, Medeiros LJ, Wang S. TP53 Mutations with a Normal Karyotype in Myelodysplastic Syndromes and Cytopenia(s) of Unknown Significance. Laboratory Investigation-106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 97(Supplement 1):384A-384A, 2017.
22. Quesada AE, Huang RSP, Luthra R, Patel KP, Hodges K, Ok CY, Routbort MJ, Bueso-Ramos CE, Medeiros LJ, Kanagal-Shamanna R. Genetic Landscape of Non-R882 DNMT3A Mutations Is Distinct from DNMT3A R882 Mutations. Laboratory Investigation- 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 97(Supplement 1):371A-371A, 2017.
23. Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin C, Kanagal-Shamana R, Wang SA, Jorgensen JL, Medeiros L, Ok CY. Mixed Phenotype Acute Leukemia Contains Heterogeneous Genetic Mutations by Next-Generation Sequencing. Journal of Molecular Diagnostics-Annual Meeting of the Association for Molecular Pathology (AMP) 18(6):961-961, 2016.
24. Almohammedsalim AA, Luthra R, Ok CY, Loghavi S, Mehrotra M, Abraham R, Harmon M, Lu X, Medeiros LJ, Patel KP, Kanagal-Shamanna R. Single Nucleotide Polymorphism-Array-Based Comparative Genomic Hybridization Analysis of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Study of 168 Cases with Comparison to Traditional Genetic Testing Methods. Journal of Molecular Diagnostics-Annual Meeting of the Association for Molecular Pathology (AMP) 17(6):773-773, 2015.
25. OK CY. Salim AA, Loghavi S, Luthra R, Routbort MJ, Singh RR, Zuo Z, Medeiros LJ, Patel KP. Solving a 10-year old enigma with next generation sequencing-based assay. The Association of Molecular Pathology Annual Meeting, November 5-7, 2015, Austin, TX, USA, 2015.
26. OK CY, Loghavi S, Salim AA, Chen H, Kanagal-Shamanna R, Chowdhuri SR, Broaddus RR, Lazar AJ, Rashid A, Manekia JH, Barkoh BA, Medeiros LJ, Singh RR, Routbort MJ, Luthra R, Patel KP. To confirm and not to confirm, that is the question for equivocal NGS findings. The Association of Molecular Pathology Annual Meeting, November 5-7, 2015, Austin, TX, USA, 2015.
27. OK CY, Yang H, Villarreal J, Barkoh BA, Routbort MJ, Singh RR, Mantha GS, Lu H, Medeiros LJ, Luthra R, Patel KP. Development of a decision support system for specimen accessioning and uniform triaging of oncologic molecular testing. The Association of Molecular Pathology Annual Meeting, November 5-7, 2015, Austin, TX, USA, 2015.
28. Li L, Xu-Monette ZY, Ok CY, Manyam GC, Visco C, Tzankov A, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu YL, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Farnen JP, Moller MB, Piris MA, Winter JN, Medeiros LJ, Young KH. Nuclear coexpression of NF-kappa B subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium. Clinical Lymphoma Myeloma & Leukemia-20th International Hematologic Malignancies 2014 Conference 15(Supplement 1):S224-S224, 2015.
29. Ok CY, Salim AA, Luthra R, Patel KP. Next Generation Sequencing-based Monitoring for Minimal Residual Disease in Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia-20th International Hematologic Malignancies 2014 Conference 15(Supplement 1):S196-S196, 2015.
30. Loghavi S, Broaddus R, Daniels M, Meric-Bernstam F, Chen K, Strong L, Almohammedsalim A, Ok CY, Brusco L, Kopetz, S, Lu, K, Lee, J, Medeiros LJ, Singh R, Patel K, Luthra R, Routbort M. Dealing With the Incidental: Experiences Implementing the ACMG Guidelines for Reporting Germline Findings in a Comprehensive Somatic Mutation Assay. Modern Pathology-104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 28(Supplement 2):460A, 2015.
31. Sakhdari A, Moghaddam PA, Ok CY, Toniaszewicz K, Cosar E, Hutchinson L. NGS Sequencing Augments Cytologic Evaluation of Pancreatic Cyst Fluids. Modern Pathology-104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 28(Supplement 2):447A, 2015.
32. Ok CY, Salim A, Loghavi S, Luthra R, Routbort M, Singh R, Zuo Z, Pierce S, Garcia-Manero G, Kantarjian H, Cortes J, Ravandi F, Andreef M, Medeiros LJ, Patel K. DNMT3A Mutation as a Molecular Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia. Modern Pathology-104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 28(Supplement 2):370A, 2015.
33. Loghavi S, Kanagal-Shamanna R, Ok CY, Almohammedsalim A, Bueso-Ramos C, Routbort M, Mehrotra M, Verstovsek S, Kantarjian H, Medeiros LJ, Luthra R, Patel K. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Megakaryocytic Features and Increased Vasculr Proliferation. Modern Pathology-104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 28(Supplement 2):361A, 2015.
34. Ok CY, Xu-Monette ZY, Tzankov A, Visco C, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJM, Farnen JP, Møller MB, Winter JN, Piris MA, Medeiros LJ, Young KH.. Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma. ASH, 2014. e-Pub 2014. PMID: 25124685.
35. Ok CY, Xu-Monette ZY, Visco C, Tzankov A, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ai W, Ponzoni M, Ferreri AJM, Farnen JP, Møller MB, Bueso-Ramos CE, Winter JN, Piris MA, Medeiros LJ, Young KH. Prevalence and Clinical Implications of Epstein-Barr Virus Infection in de novo Diffuse Large B-Cell Lymphoma in Western Countries: A report from The International DLBCL Rituximab-CHOP Consortium. Clinical Lymphoma Myeloma & Leukemia-9th International Hematologic Malignancies 2013 Conference 14(Supplement 3):S144-S145, 2014.
36. Ok CY, Tzankov A, Orazi A, Bhagat G, Hsi ED, Ponzoni M, Møller MB, Piris MA, Medeiros LJ, Young KH. Immunohistochemical profiling of NF-κB subunit components in diffuse large B-cell lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study. USCAP, 2014.
37. Goswami RS, Ok CY, Patel KP, Wang SA, Routbort MJ, Manekia JH, Jabbar KJ, Barkoh BA, Medeiros LJ, Singh RR, Luthra R. Novel Mutations inTherapy-Related and De Novo Myelodysplasia: Results from a Next-Generation Sequencing Pilot Study. Laboratory Investigation-103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 94(Supplement 1):461A, 2014.
38. Ok CY, Tzankov A, Orazi A, Bhagat G, Hsi ED, Ponzoni M, Moller MB, Piris MA, Medeiros LJ, Young KH. Single Nucleotide Variation (SNV) of PRDM1 and Clinical Impact in De Novo Diffuse Large B Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study. Laboratory Investigation-103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 94(Supplement 1):368A, 2014.
39. Ok CY, Patel KP, Wang SA, Routbort MJ, Fu B, Singh R, Kanagal-Shamanna R, LJ, Luthra R. Multigene Mutational Analysis Using Next Generation Sequencing (NGS) of 484 Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Laboratory Investigation-103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 94(Supplement 1):367A, 2014.
40. Zhang L, Xie W, Ok CY, Medeiros LJ, Wang SA. Myeloproliferative Neoplasms Occurring in Patients with a Cancer History. Laboratory Investigation-102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 93(Supplement 1):370A, 2013.
41. Ok CY, Zuo Z, Garcia-Manero G, Medeiros LJ, Wang SA. Implications of Using the Revised International Prognostic Scoring System (IPSS-R) For Patients with Therapy-related Neoplasms. Laboratory Investigation-102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 93(Supplement 1):354A, 2013.
42. Ok CY, Wang SA, Lin P, Medeiros LJ, Jorgensen JL. Mixed phenotype acute leukemia: experience in a single institution. USCAP 19, 2013.
43. Ok CY, Huh YO. Case #309, 2013.
44. Ok CY, Huh YO. Case #84, 2013. e-Pub 2013.
45. Ok CY, Wang SA. Case #83, 2013.
46. Ok CY, Welch M, Tomaszewicz K, Hutchinson L, Cosar EF. KRAS mutations in lipomas, atypical lipomatous tumors/well-differentiated liposarcomas (ALT) and dedifferentiated liposarcoma (DDLS). Laboratory Investigation-101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 92(Supplement 1):18A, 2012.
47. Ok CY, Zhou Y, Hu Y, Medeiros LJ, Wang SA. Ring sideroblasts and a normal karyotype in bone marrow of patients treated for primary malignancies and developed cytopenia. Modern Pathology-101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 25(Supplement 2):358A, 2012.
48. Zhou Y , Tang G ,Ok CY, Medeiros LJ, Wierda W, Wang SA. Therapy-Related Myeloid Neoplasms (t-MN) in Chronic Lymphocytic Leukemia Patients Treated with the FCR Chemotherapy Regimen. Laboratory Investigation-100th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 91(Supplement 1):334A, 2011.
49. Ok CY, Walter O, Hutchinson L, Belkin E, Wassef W, Woda B, Cosar E. KRAS mutation analysis is a good adjunct to cytologic evaluation of pancreatic cyst fluids, 2011.
50. Ok CY, Yu H, Hesse A, Snyder LM, Connor D, Sjostedt E, Pechet L, Nordell P. Evaluation of an Automated Digital Image System, Nextslide Digital Review Network, for Examination of Peripheral Blood Smears. American Journal of Clinical Pathology 134(4):690-691, 2010.

Book Chapters

1. Ok CY and Hasserjian RP. Leukocytosis and/or thrombocytosis due to abnormalities of hematopoiesis. In: Diagnosis of Blood and Bone Marrow Disorders. 1. Springer, 135-170, 2018.
2. Ok CY, Singh RR, Salim AA. Single-Cell Quantitative PCR: Advances and Potential in Cancer Diagnostics. In: Methods Mol Biol - Clinical Applications of PCR. Springer, 153-9, 2016.

Letters to the Editor

1. Thakral B, Daver N, Tang Z, Patel KP, Ok CY, Loghavi S, Khoury J, Alotaibi A, Konopleva M, Yilmaz M, Medeiros LJ.. Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leukemia and Lymphoma 61: 3243-3246, 2020.
2. Romaguera JE, Lee HJ, Tarapore R, Prabhu V, Allen J, Schalop L, Zloza A, Ok CY, Sadimin ET, Schenkel J, Badillo M, Wang M. Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment. Br J Haematol 185: 133-136, 2019.